Royal Bank of Canada’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-40,100
Closed -$3.21M 7359
2025
Q4
$3.21M Buy
+40,100
New +$2.69M ﹤0.01% 2779
2025
Q1
Sell
-6,600
Closed -$515K 6982
2024
Q4
$515K Buy
+6,600
New +$530K ﹤0.01% 4071
2024
Q2
Sell
-23,400
Closed -$2M 7247
2024
Q1
$2M Buy
23,400
+14,900
+175% +$1.17M ﹤0.01% 2925
2023
Q4
$727K Buy
+8,500
New +$735K ﹤0.01% 3934

Other funds holding HAE

Royal Bank of Canada's HAE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Haemonetics (HAE) stake by 11% in Q1 2026, selling an estimated $7.14M and leaving 857,965 shares worth $48.4M. The position accounts for 0.01% of the portfolio, ranked #930.

Royal Bank of Canada first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $81.9M in Q4 2024. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Royal Bank of Canada held 857,965 shares of Haemonetics worth $48.4M as of Q1 2026.
  • Royal Bank of Canada sold 109,628 Haemonetics shares in Q1 2026, an estimated $7.14M.
  • Haemonetics made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #930 holding.
  • Royal Bank of Canada first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Haemonetics position peaked at $81.9M in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.